Li, S., Peng, L., Tan, C., Zeng, X., Wan, X., Luo, X., . . . Li, J. (2020). Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS One.
Stile di citazione ChicagoLi, Sini, Liubao Peng, Chongqing Tan, Xiaohui Zeng, Xiaomin Wan, Xia Luo, Lidan Yi, e Jianhe Li. "Cost-Effectiveness of Ramucirumab Plus Paclitaxel As a Second-line Therapy for Advanced Gastric or Gastro-oesophageal Cancer in China." PLoS One 2020.
Citazione MLALi, Sini, et al. "Cost-Effectiveness of Ramucirumab Plus Paclitaxel As a Second-line Therapy for Advanced Gastric or Gastro-oesophageal Cancer in China." PLoS One 2020.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.